Hepatitis Therapeutics Market Size, Share, And Trend Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025

  • ID: 4479662
  • Report
  • Region: America, Europe, North America, United States
  • 80 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Bristol-Myers Squibb Co
  • Gilead Lifesciences
  • Johnson & Johnson
  • Merck & Co., Inc.,
  • MORE
The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025 according to a new report by The report, Inc. Few factors that are expected to drive the market over the forecast period include rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.

Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Further Key Findings from the Report Suggest:
  • Owing to high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2016
  • In 2016, North American region accounted for majority of revenue share of 42.9% owing to high patient awareness levels and the presence of advanced healthcare infrastructure
  • However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period owing to rapidly increasing healthcare expenditure
  • Key players include Gilead, Johnson & Johnson, Merck & Co. Inc., Bristol-Myers Squibb Company, and AbbVie Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Bristol-Myers Squibb Co
  • Gilead Lifesciences
  • Johnson & Johnson
  • Merck & Co., Inc.,
  • MORE
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Snapshot

Chapter 3. Hepatitis Therapeutics Market Variables, Trends & Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis - Porter's
3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015

Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million)
4.2. Hepatitis A
4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.3. Hepatitis B
4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.4. Hepatitis C
4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.5. Others
4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)

Chapter 5. Hepatitis Therapeutics Market: Regional Outlook, By Disease Type
5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million)
5.2. North America
5.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.2. U.S.
5.2.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.3. Canada
5.2.3.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3. Europe
5.3.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.2. Germany
5.3.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.3. UK
5.3.3.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.2. China
5.4.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.3. Japan
5.4.3.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5. Latin America
5.5.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.2. Brazil
5.5.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.3. Mexico
5.5.3.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6. Middle East & Africa
5.6.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6.2. South Africa
5.6.2.1. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)

Chapter 6. Competitive Landscape
6.1. Gilead Lifesciences
6.1.1. Company overview
6.1.2. Financial performance
6.1.3. Product benchmarking
6.1.4. Strategic initiatives
6.2. Bristol-Myers Squibb Co
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Biocon
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. AbbVie
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. Merck & Co., Inc.,
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. Johnson & Johnson
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives

List of Tables

Table 1 Hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 2 North America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 3 U.S. hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 4 Canada hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 5 Europe hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 6 Germany hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 7 UK hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 8 Asia Pacific hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 9 China hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 10 Japan hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 11 Latin America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 12 Brazil hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 13 Mexico hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 14 Middle East & Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Table 15 South Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Hepatitis therapeutics market, Heat Map Analysis
FIG. 13 Hepatitis therapeutics market product outlook key takeaways
FIG. 14 Hepatitis therapeutics market: Disease type movement analysis
FIG. 15 Hepatitis A market, 2014 - 2025 (USD Million)
FIG. 16 Hepatitis B market, 2014 - 2025 (USD Million)
FIG. 17 Hepatitis C market, 2014 - 2025 (USD Million)
FIG. 18 Other hepatitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 19 Regional outlook, 2015 & 2024
FIG. 20 North America hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 21 U.S. hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 Canada hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Europe hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Germany hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 UK hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 Asia Pacific hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 China hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 Japan hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 Latin America hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 Brazil hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 Mexico hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 MEA hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 South Africa hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Gilead Lifesciences
  • Bristol-Myers Squibb Co
  • Biocon
  • AbbVie
  • Merck & Co., Inc.,
  • Johnson & Johnson
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll